22 Feb 2024 • The guideline panel made 7 recommendations. Fecal microbiota–based therapies were deemed effective therapy to prevent recurrent C difficile in select patients.

• In immunocompetent adults with recurrent C difficile infection, the AGA suggests select use of fecal microbiota–based therapies on completion of standard of care antibiotics to prevent recurrence.
• In mildly or moderately immunocompromised adults with recurrent C difficile infection, the AGA suggests select use of conventional fecal microbiota transplant.
• In severely immunocompromised adults, the AGA suggests against the use of any fecal microbiota–based therapies to prevent recurrent C difficile.
• In adults hospitalized with severe or fulminant C difficile not responding to standard of care antibiotics, the AGA suggests select use of conventional fecal microbiota transplant.

The AGA suggests against the use of conventional fecal microbiota transplant as treatment for inflammatory bowel diseases or irritable bowel syndrome, except in the context of clinical trials.

Source: AGA | Read full story